Cummings, 2011 - Google Patents
Alzheimer's disease clinical trials: changing the paradigmCummings, 2011
- Document ID
- 4084242653901201283
- Author
- Cummings J
- Publication year
- Publication venue
- Current psychiatry reports
External Links
Snippet
Alzheimer's disease (AD) is rapidly becoming a public health emergency; there are currently 35 million victims worldwide, with a projected growth to more than 100 million by 2050 if means to delay the onset, slow the progression, or ameliorate the symptoms are not found …
- 206010001897 Alzheimer's disease 0 title abstract description 82
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Self et al. | Emerging diagnostics and therapeutics for Alzheimer disease | |
Frisoni et al. | The probabilistic model of Alzheimer disease: the amyloid hypothesis revised | |
Ringman et al. | Genetic heterogeneity in Alzheimer disease and implications for treatment strategies | |
Takahashi et al. | Opposing effects of progranulin deficiency on amyloid and tau pathologies via microglial TYROBP network | |
Mufson et al. | Nerve growth factor pathobiology during the progression of Alzheimer’s disease | |
Stanley et al. | Changes in insulin and insulin signaling in Alzheimer’s disease: cause or consequence? | |
Imbimbo et al. | Pathophysiology of Alzheimer's disease | |
Murray et al. | Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias | |
Yu et al. | Apolipoprotein E in Alzheimer's disease: an update | |
Sabuncu et al. | The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects | |
Rhinn et al. | Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease | |
Coarelli et al. | Recent advances in understanding dominant spinocerebellar ataxias from clinical and genetic points of view | |
Kulstad et al. | Differential modulation of plasma β-amyloid by insulin in patients with Alzheimer disease | |
Liao et al. | Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models | |
Desikan et al. | Heart fatty acid binding protein and Aβ-associated Alzheimer’s neurodegeneration | |
Guest et al. | Early diagnosis and targeted treatment strategy for improved therapeutic outcomes in Alzheimer’s disease | |
Sun et al. | APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease | |
Tong et al. | Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men | |
Sohn et al. | ApoE4 attenuates autophagy via FoxO3a repression in the brain | |
Young et al. | APOE effects on regional tau in preclinical Alzheimer’s disease | |
Li et al. | Genome-wide association and interaction studies of CSF T-tau/Aβ42 ratio in ADNI cohort | |
Koran et al. | Genetic interactions found between calcium channel genes modulate amyloid load measured by positron emission tomography | |
Krance et al. | Reciprocal predictive relationships between amyloid and tau biomarkers in Alzheimer's disease progression: an empirical model | |
Keene et al. | Epidemiology, pathology, and pathogenesis of Alzheimer disease | |
Kerchner et al. | The role of aging in Alzheimer’s disease |